First-line therapy for chronic lymphocytic leukemia in patients older than 79 years is feasible and achieves good results: A FILO retrospective study.

scientific article published on 22 November 2016

First-line therapy for chronic lymphocytic leukemia in patients older than 79 years is feasible and achieves good results: A FILO retrospective study. is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1002/HON.2370
P698PubMed publication ID27878835

P50authorGuillaume CartronQ38803376
Anne QuinquenelQ61196720
Anne-Sophie MichalletQ87908815
P2093author name stringPierre Morel
Stéphane Lepretre
Marie Christine Béné
Véronique Leblond
Florence Cymbalista
Pierre Feugier
Bruno Cazin
Jehan Dupuis
Loic Ysebaert
Richard Lemal
Phi Linh Nguyen-Thi
Cécile Tomowiak
Godelieve Meunier
Thérèse Aurran
Annie Brion
Daniel Ré
Marie Sarah Dilhuydy
P2860cites workGuidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelinesQ24616084
Analysis of age, estimated creatinine clearance and pretreatment hematologic parameters as predictors of fludarabine toxicity in patients treated for chronic lymphocytic leukemia: a CALGB (9011) coordinated intergroup studyQ33343164
Interactions between comorbidity and treatment of chronic lymphocytic leukemia: results of German Chronic Lymphocytic Leukemia Study Group trialsQ33695990
Treatment practice in the elderly patient with chronic lymphocytic leukemia-analysis of the combined SEER and Medicare databaseQ33846793
Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trialQ34141305
A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysisQ34282319
Exclusion of older patients from ongoing clinical trials for hematological malignancies: an evaluation of the National Institutes of Health Clinical Trial RegistryQ34359352
Rating chronic medical illness burden in geropsychiatric practice and research: application of the Cumulative Illness Rating ScaleQ34425278
Chemoimmunotherapy with fludarabine and rituximab produces extended overall survival and progression-free survival in chronic lymphocytic leukemia: long-term follow-up of CALGB study 9712Q34879367
Management and geriatric assessment of cancer in the elderlyQ35782952
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic LeukemiaQ36490049
Relative value of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemiaQ36843749
International Society of Geriatric Oncology consensus on geriatric assessment in older patients with cancerQ36925135
Comorbid conditions and survival in unselected, newly diagnosed patients with chronic lymphocytic leukemiaQ37059754
Treatment of elderly patients with chronic lymphocytic leukemiaQ37386705
Multidimensional geriatric evaluation for older cancer patients as a clinical and research toolQ37501072
Age at diagnosis and the utility of prognostic testing in patients with chronic lymphocytic leukemiaQ37517160
Presenting features and outcome of chronic lymphocytic leukemia patients diagnosed at age 80 years or more. An ICLLSG studyQ37879960
Chronic lymphocytic leukemia in less fit patients: "slow-go".Q37903038
Optimal management of older patients with chronic lymphocytic leukemia: some facts and principles guiding therapeutic choicesQ37940136
Treatment of older patients with chronic lymphocytic leukemia: key questions and current answersQ38169637
Past, present and future role of chlorambucil in the treatment of chronic lymphocytic leukemiaQ38248969
Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): a randomised, multicentre, open-label phase 3 trialQ38424831
Trends in long-term survival of patients with chronic lymphocytic leukemia from the 1980s to the early 21st centuryQ40118546
Unbiased estimates of long-term net survival of hematological malignancy patients detailed by major subtypes in France.Q43423234
Development and validation of a prognostic index for 1-year mortality in older adults after hospitalizationQ43643159
Does a geriatric oncology consultation modify the cancer treatment plan for elderly patients?Q43737974
Improving survival in patients with chronic lymphocytic leukemia (1980-2008): the Hospital Clinic of Barcelona experienceQ44079638
Comorbidity and functional status are independent in older cancer patientsQ44747457
Development and validation of a prognostic index for 4-year mortality in older adults.Q45975392
ESH–SIOG International Conference on Haematological Malignancies in the ElderlyQ51742814
Comprehensive geriatric assessment predicts tolerance to chemotherapy and survival in elderly patients with advanced ovarian carcinoma: a GINECO study.Q51927016
SF3B1 mutations correlated to cytogenetics and mutations in NOTCH1, FBXW7, MYD88, XPO1 and TP53 in 1160 untreated CLL patients.Q52644149
Exclusion of older people from clinical trials: professional views from nine European countries participating in the PREDICT study.Q53087437
Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting ConditionsQ56657194
P433issue4
P921main subjectchronic lymphocytic leukemiaQ1088156
P304page(s)671-678
P577publication date2016-11-22
P1433published inHematological OncologyQ15762617
P1476titleFirst-line therapy for chronic lymphocytic leukemia in patients older than 79 years is feasible and achieves good results: A FILO retrospective study
P478volume35

Reverse relations

Q58035743Combined Immunosuppressive Therapy Induces Remission in Patients With Severe Type B Insulin Resistance: A Prospective Cohort Studycites workP2860

Search more.